iBio, Inc. (IBIO) |
|
1.29 -0.08 (-5.84%)
|
02-08 09:35 |
|
Open: |
0.9545 |
Pre. Close: |
1.37 |
|
High:
|
1.31 |
Low:
|
1.26 |
|
Volume:
|
205,495 |
Market Cap:
|
14(M) |
|
|
|
Technical analysis |
as of: 2023-02-07 4:29:11 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.74  One year: 2.03 |
| Support: |
Support1: 0.85 Support2: 0.46 |
| Resistance: |
Resistance1: 1.49 Resistance2: 1.74 |
| Pivot: |
0.78 |
| Moving Average: |
MA(5): 0.9 MA(20): 0.77
MA(100): 2.19  MA(250): 5.36 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 57.4 %D(3): 45.5 |
| RSI: |
RSI(14): 78.3 |
| 52-week: |
High: 16.5 Low: 0.23 |
| Average Vol(K): |
3-Month: 783 (K) 10-Days: 1,571 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IBIO ] has closed above the upper band by 38.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.49 - 1.5 |
1.5 - 1.5 |
|
Low:
|
0.87 - 0.88 |
0.88 - 0.88 |
|
Close:
|
1.36 - 1.37 |
1.37 - 1.38 |
|
Company Description |
|
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas. |
Headline News |
Wed, 08 Feb 2023
Current and Future Analysis of Yellow Fever Treatment Market With New Business Strategies and Forecast by 2030 - openPR
Wed, 08 Feb 2023
A glimpse at iBio Inc.'s potential climb to old highs - The Dwinnex
Tue, 07 Feb 2023
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
Tue, 07 Feb 2023
Healthcare Stocks on the Move Tuesday: KPRX, IBIO, CYAD, OSH, CHEK, REVB, CVAC, MYMD - InvestorsObserver
Tue, 07 Feb 2023
Should You Buy Ibio Inc (IBIO) Stock Tuesday? - InvestorsObserver
Mon, 06 Feb 2023
Plant-based Vaccines Market is Booming Worldwide | Mitsubishi ... - Digital Journal
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
218 (M) |
|
% Held by Insiders
|
2.167e+008 (%) |
|
% Held by Institutions
|
1.2 (%) |
|
Shares Short
|
11,600 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.038e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.16 |
|
EPS Est Next Year
|
-0.21 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
520.1 |
|
Return on Equity (ttm)
|
-15.9 |
|
Qtrly Rev. Growth
|
2.17e+006 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.08 |
|
Qtrly Earnings Growth
|
-0.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-32 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
182.4 |
|
Price to Cash Flow
|
-16.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.117e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
